These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32393286)

  • 21. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
    Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
    Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
    Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
    Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
    Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
    Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon
    Ohara G; Okauchi S; Sasatani Y; Shiozawa T; Yamada H; Miyazaki K; Satoh H
    In Vivo; 2020; 34(3):1459-1462. PubMed ID: 32354946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report.
    Falla-Martinez JC; Espinosa D; Baena JC; Rodriguez LX; Sua LF; Zambrano AR
    J Med Case Rep; 2019 May; 13(1):144. PubMed ID: 31088573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
    Wang XF; Zhao QT; Chen C
    Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
    [No Abstract]   [Full Text] [Related]  

  • 28. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.
    Yang H; Cai L; Zhang Y; Tan H; Deng Q; Zhao M; Xu X
    J Mol Diagn; 2014 Sep; 16(5):558-563. PubMed ID: 24994671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
    Fang W; Huang Y; Gan J; Shao YW; Zhang L
    J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
    [No Abstract]   [Full Text] [Related]  

  • 30. Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.
    Bordi P; Tiseo M; Bortesi B; Naldi N; Buti S; Ardizzoni A
    Tumori; 2014; 100(1):e20-3. PubMed ID: 24675505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Metastatic Brain Tumor from Lung Adenocarcinoma Presenting a Unique Radiographic Pattern during Afatinib Treatment:A Case Report].
    Miyamoto J; Nakagawa T; Hirayama H
    No Shinkei Geka; 2018 Mar; 46(3):213-217. PubMed ID: 29567871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma.
    Wang G; He H
    Clin Radiol; 2024 May; 79(5):e784. PubMed ID: 38402088
    [No Abstract]   [Full Text] [Related]  

  • 34. Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
    Lin CH; Lin MT; Kuo YW; Ho CC
    Lung Cancer; 2014 Sep; 85(3):479-80. PubMed ID: 24999085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.
    Zhang YJ; Li H; Zhong R; Chen W; Kou G; Liu G; Cheng Y
    Clin Lung Cancer; 2020 Sep; 21(5):e493-e496. PubMed ID: 32418825
    [No Abstract]   [Full Text] [Related]  

  • 36. Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.
    Wei YF; Lim CK; Tsai MS; Huang MS; Chen KY
    Clin Lung Cancer; 2019 May; 20(3):e274-e283. PubMed ID: 30930121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
    Fang YF; Liu PC
    Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
    Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
    Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
    Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
    Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.